阿尔茨海默病的肠-大脑轴:肠道微生物群如何调节微质功能
Huan Wang1, Feifan Yang2, Zhejianyi Gao1
1College of Acupuncture-Moxibustion and Tuina, Liaoning University of Traditional Chinese Medicine, Shenyang, China.
Frontiers in aging
|December 8, 2025
概括
肠道微生物群通过影响小质细胞,大脑的免疫细胞,影响阿尔茨海默病 (AD). 调节肠道微生物群为AD治疗提供了潜在的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
背景情况:
- 阿尔茨海默氏病 (AD) 的发病包括β-粉样蛋白,tau病理和神经炎症.
- 中枢神经系统免疫细胞微质细胞在AD相关的神经炎症和认知功能中发挥着至关重要的作用.
- 新出现的证据将肠道微生物群的失调与阿尔茨海默病的发展联系起来.
研究的目的:
- 审查肠道微生物群对微质细胞的直接和间接影响.
- 探索肠道微生物群在阿尔茨海默氏病的发病过程中的作用.
- 讨论针对AD的基于肠道微生物群的治疗策略.
主要方法:
- 在AD.研究肠道微生物群-微质轴的研究文献综述.
- 对将肠道微生物群与微质表型和功能联系起来的机制的分析.
- 综合目前针对AD的治疗方法,以肠道微生物群为目标.
主要成果:
- 肠道微生物群及其衍生物通过直接的代谢物作用和间接的免疫/神经递质调节影响微质.
- 由肠道微生物群驱动的微质失调有助于AD中的神经炎症.
- 治疗策略包括饮食干预,益生菌,便微生物群移植和传统中医.
结论:
- 肠道微生物群-微质轴是阿尔茨海默病的一个重要因素.
- 准肠道微生物群为AD提供了有希望的治疗途径.
- 进一步的研究是必不可少的,以充分阐明和优化这些干预措施的AD治疗.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764


